Dear all I encountered operational challege were during SIA, specifically OBR using mOPV2 antigen. I observed that the fixed post team were given only bOPV which is the right antigen for routine while ignoring the purpose of the campaign (mOPV2 not given). They were intructed to give both mOPV2 and...

In its January 2015 meeting, the WHO Executive Board called on all Member States to accelerate preparation for a globally coordinated switch from trivalent to bivalent OPV in April 2016. The Board’s request follows the WHO SAGE announcement in October 2014 that preparations are on track for this imp...